

Giovambattista De Sarro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6046557/publications.pdf>

Version: 2024-02-01

308
papers

9,660
citations

47409

49
h-index

87275

74
g-index

310
all docs

310
docs citations

310
times ranked

11854
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand?. <i>Current Neuropharmacology</i> , 2023, 21, 1691-1713.	1.4	4
2	Autosomal dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease. <i>Medicinal Research Reviews</i> , 2022, 42, 629-640.	5.0	7
3	Direct-acting Antivirals Inducing HCV-RNA Sustained Suppression Improve Xerophthalmia in HCV-infected Patients. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2022, 17, 156-160.	0.4	1
4	Colchicine in Managing Skin Conditions: A Systematic Review. <i>Pharmaceutics</i> , 2022, 14, 294.	2.0	22
5	High-Intensity, Low-Frequency Pulsed Electromagnetic Field as an Odd Treatment in a Patient with Mixed Foot Ulcer: A Case Report. <i>Reports</i> , 2022, 5, 3.	0.2	6
6	N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy. <i>Molecular Neurobiology</i> , 2022, , 1.	1.9	8
7	The Pharmacological Treatment of Pediatric Vertigo. <i>Children</i> , 2022, 9, 584.	0.6	3
8	Vitamin D Deficiency in Women with Breast Cancer: A Correlation with Osteoporosis? A Machine Learning Approach with Multiple Factor Analysis. <i>Nutrients</i> , 2022, 14, 1586.	1.7	12
9	Molecular Pathways Involved in the Anti-Cancer Activity of Flavonols: A Focus on Myricetin and Kaempferol. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4411.	1.8	24
10	Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role. <i>Pharmaceutics</i> , 2022, 15, 589.	1.7	11
11	mGlu3 metabotropic glutamate receptors as a target for the treatment of absence epilepsy: preclinical and human genetics data. <i>Current Neuropharmacology</i> , 2022, 20, .	1.4	3
12	Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5282.	1.8	10
13	Diamagnetic Therapy in a Patient with Complex Regional Pain Syndrome Type I and Multiple Drug Intolerance: A Case Report. <i>Reports</i> , 2022, 5, 18.	0.2	4
14	Effectiveness and Safety of ANTI SARS-CoV-2 Vaccination in Transplant Patients Treated with Immunosuppressants: A Real-World Pilot Study with a 1-Year Follow-Up. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 6103.	1.3	3
15	Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study. <i>Life</i> , 2022, 12, 965.	1.1	4
16	Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients. <i>International Urology and Nephrology</i> , 2021, 53, 171-175.	0.6	5
17	Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients. <i>Journal of Nephrology</i> , 2021, 34, 451-458.	0.9	2
18	First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. <i>Epilepsia</i> , 2021, 62, 529-541.	2.6	35

#	ARTICLE	IF	CITATIONS
19	Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells. <i>Toxicology Reports</i> , 2021, 8, 816-821.	1.6	1
20	Blood-brain Barrier Dysfunction and Extension of Time Window for Thrombolysis: A Limitation not Evaluated. <i>Current Vascular Pharmacology</i> , 2021, 19, 585-586.	0.8	0
21	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 684638.	1.6	33
22	Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury. <i>PLoS ONE</i> , 2021, 16, e0251819.	1.1	15
23	Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. <i>Nutrients</i> , 2021, 13, 2031.	1.7	14
24	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α -Blockers and 5-Alpha Reductase Inhibitors. <i>Uro</i> , 2021, 1, 82-98.	0.3	2
25	Biomarkers in unstable carotid plaque: Physiopathology and Prediction. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2021, 19, .	0.4	4
26	Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression. <i>Neuropharmacology</i> , 2021, 198, 108782.	2.0	33
27	Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11639.	1.8	4
28	Is there a link between Non melanoma skin cancer and hydrochlorothiazide?. <i>Current Drug Safety</i> , 2021, 16, .	0.3	6
29	Vitamin D Serum Levels in Subjects Tested for SARS-CoV-2: What Are the Differences among Acute, Healed, and Negative COVID-19 Patients? A Multicenter Real-Practice Study. <i>Nutrients</i> , 2021, 13, 3932.	1.7	21
30	Myotoxicity Induced by Antiepileptic Drugs: Could be a Rare but Serious Adverse Event?. <i>Psychopharmacology Bulletin</i> , 2021, 51, 105-116.	0.0	0
31	Asthma Control during COVID-19 Lockdown in Patients with Severe Asthma under Biological Drug Treatment. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 12089.	1.3	1
32	Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12936.	1.2	8
33	The risks of polypharmacy in ambulatory and home care patients affected with dementia: The PharE Study. <i>Alzheimer's and Dementia</i> , 2021, 17, e053117.	0.4	0
34	Clinically relevant drug interactions between statins and antidepressants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 227-239.	0.7	24
35	A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report. <i>Current Drug Safety</i> , 2020, 15, 69-72.	0.3	7
36	Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats. <i>Molecular Neurobiology</i> , 2020, 57, 408-421.	1.9	53

#	ARTICLE	IF	CITATIONS
37	Modeling poststroke epilepsy and preclinical development of drugs for poststroke epilepsy. <i>Epilepsy and Behavior</i> , 2020, 104, 106472.	0.9	7
38	The Art of Safe and Judicious Deprescribing in an Elderly Patient: A Case Report. <i>Geriatrics (Switzerland)</i> , 2020, 5, 57.	0.6	3
39	IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy. <i>Neurotherapeutics</i> , 2020, 17, 2004-2014.	2.1	24
40	The risk of polypharmacy and potentially inappropriate drugs in residential care dementia patients: tips from the PharE study. <i>Aging Clinical and Experimental Research</i> , 2020, 33, 1909-1917.	1.4	6
41	Pain Modulation in WAG/Rij Epileptic Rats (A Genetic Model of Absence Epilepsy): Effects of Biological and Pharmacological Histone Deacetylase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 549191.	1.6	13
42	Pharmacokinetic considerations about antiseizure medications in the elderly. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 983-995.	1.5	9
43	Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin. <i>Molecular Neurobiology</i> , 2020, 57, 4778-4789.	1.9	11
44	HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic β -Cell Glucagon Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2941-2952.	1.1	10
45	Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5846.	1.8	29
46	Management of status epilepticus in patients with liver or kidney disease: a narrative review. <i>Expert Review of Neurotherapeutics</i> , 2020, 21, 1-14.	1.4	4
47	The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116903.	0.3	18
48	Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. <i>Pharmacological Research</i> , 2020, 159, 105019.	3.1	11
49	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 1457-1463.	0.9	40
50	Neural Modulation of the Primary Auditory Cortex by Intracortical Microstimulation with a Bio-Inspired Electronic System. <i>Bioengineering</i> , 2020, 7, 23.	1.6	6
51	Does screening for adverse effects improve health outcomes in epilepsy?. <i>Neurology</i> , 2020, 95, e239-e246.	1.5	6
52	Histopathological findings in a COVID-19 patient affected by ischemic gangrenous cholecystitis. <i>World Journal of Emergency Surgery</i> , 2020, 15, 43.	2.1	51
53	How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010-2016. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	4
54	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1227.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Analgesic and Anti-Inflammatory Effects of Perampanel in Acute and Chronic Pain Models in Mice: Interaction With the Cannabinergic System. <i>Frontiers in Pharmacology</i> , 2020, 11, 620221.	1.6	10
56	Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. <i>PLoS ONE</i> , 2020, 15, e0241575.	1.1	38
57	Antiepileptic Drugs and Bone Health: Current Concepts. <i>Psychopharmacology Bulletin</i> , 2020, 50, 36-44.	0.0	4
58	Can we "seize" the gut microbiota to treat epilepsy?. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 750-764.	2.9	60
59	Immediate and controlled-release pregabalin for the treatment of epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1167-1177.	1.4	6
60	Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis. <i>Brain Research Bulletin</i> , 2019, 153, 133-142.	1.4	24
61	Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. <i>Scientific Reports</i> , 2019, 9, 13983.	1.6	51
62	25-Hydroxy Vitamin D Detection Using Different Analytic Methods in Patients with Migraine. <i>Journal of Clinical Medicine</i> , 2019, 8, 895.	1.0	19
63	Cognitive impairment in the WAG/Rij rat absence model is secondary to absence seizures and depressive-like behavior. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109652.	2.5	32
64	Hypertension, seizures, and epilepsy: a review on pathophysiology and management. <i>Neurological Sciences</i> , 2019, 40, 1775-1783.	0.9	51
65	Antiepileptogenic effects of Ethosuximide and Levetiracetam in WAG/Rij rats are only temporary. <i>Pharmacological Reports</i> , 2019, 71, 833-838.	1.5	18
66	Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 25-39.	0.9	6
67	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review. <i>Dermatologic Therapy</i> , 2019, 32, e12748.	0.8	23
68	Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation. <i>Current Drug Safety</i> , 2019, 14, 67-71.	0.3	1
69	What is the Current Role for Vitamin D and the Risk of Stroke?. <i>Current Neurovascular Research</i> , 2019, 16, 178-183.	0.4	8
70	Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice. <i>Psychopharmacology Bulletin</i> , 2019, 49, 70-79.	0.0	6
71	Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 4116-4125.	2.0	16
72	Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. <i>Pharmacological Research</i> , 2018, 129, 274-294.	3.1	47

#	ARTICLE	IF	CITATIONS
73	Isolated Hand Palsy in National Institutes of Health Stroke Scale (NIHSS): Is It Useful?. <i>Western Journal of Emergency Medicine</i> , 2018, 19, 524-526.	0.6	4
74	Efficacy and Safety of Elbasvirâ€Grazoprevir Fixed Dose in the Management of Poly-treated HCV Patients: Evidence From Realâ€Life Clinical Practice. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1248-1253.	1.0	3
75	Perampanel chronic treatment does not induce tolerance and decreases tolerance to clobazam in genetically epilepsy prone rats. <i>Epilepsy Research</i> , 2018, 146, 94-102.	0.8	3
76	C-Kit receptor and tryptase expressing mast cells correlate with angiogenesis in breast cancer patients. <i>Oncotarget</i> , 2018, 9, 7918-7927.	0.8	16
77	Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review. <i>Current Pharmaceutical Design</i> , 2018, 23, 5606-5624.	0.9	6
78	Drug-Drug Interactions in Cocaine-users and their Clinical Implications. <i>Current Drug Abuse Reviews</i> , 2018, 10, 25-30.	3.4	11
79	Genetically epilepsy-prone rats (GEPRs) and DBA/2 mice: Two animal models of audiogenic reflex epilepsy for the evaluation of new generation AEDs. <i>Epilepsy and Behavior</i> , 2017, 71, 165-173.	0.9	35
80	Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. <i>Behavioural Brain Research</i> , 2017, 321, 157-169.	1.2	77
81	Cerebral small vessel disease predisposes to temporal lobe epilepsy in spontaneously hypertensive rats. <i>Brain Research Bulletin</i> , 2017, 130, 245-250.	1.4	18
82	Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 515-522.	1.0	17
83	Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressiveâ€like behavior. <i>Epilepsia</i> , 2017, 58, 231-238.	2.6	48
84	Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model. <i>Neurotherapeutics</i> , 2017, 14, 1134-1147.	2.1	32
85	Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. <i>Drug, Healthcare and Patient Safety</i> , 2017, Volume 9, 25-37.	1.0	61
86	Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients. <i>Current Drug Safety</i> , 2017, 12, 171-177.	0.3	17
87	The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 311-325.	0.8	9
88	The Anticonvulsant Activity of a Flavonoid-Rich Extract from Orange Juice Involves both NMDA and GABA-Benzodiazepine Receptor Complexes. <i>Molecules</i> , 2016, 21, 1261.	1.7	43
89	Inâ€Vivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents. <i>ChemMedChem</i> , 2016, 11, 1812-1818.	1.6	36
90	Pharmacovigilance in the Elderly (Phare Study): Use of Inappropriate Drugs and Adverse Events in Elderly Home Care Patients Affected with Dementia: A Study from ASP Catanzaro, Italy. <i>Alzheimer's and Dementia</i> , 2016, 12, P429.	0.4	0

#	ARTICLE	IF	CITATIONS
91	mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. <i>Pharmacological Research</i> , 2016, 107, 333-343.	3.1	144
92	Managing epilepsy in the third millenium: Recent achievements and future perspectives. <i>Pharmacological Research</i> , 2016, 113, 332-334.	3.1	2
93	Upholding WAG/Rij rats as a model of absence epileptogenesis: Hidden mechanisms and a new theory on seizure development. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 388-408.	2.9	77
94	Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl-2- ω -chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2016, 791, 523-534.	1.7	23
95	Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. <i>Frontiers in Neuroendocrinology</i> , 2016, 42, 76-92.	2.5	51
96	Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. <i>Pharmacological Research</i> , 2016, 113, 276-289.	3.1	48
97	Anticonvulsive Activity in Audiogenic DBA/2 Mice of 1,4-Benzodiazepines and 1,5-Benzodiazepines with Different Activities at Cerebellar Granule Cell GABAA Receptors. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 539-547.	1.1	4
98	Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 216-226.	3.2	42
99	Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 107, 315-332.	3.1	30
100	Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression. <i>Journal of Psychiatric Research</i> , 2016, 78, 1-10.	1.5	28
101	Genetics of reflex seizures and epilepsies in humans and animals. <i>Epilepsy Research</i> , 2016, 121, 47-54.	0.8	60
102	P060. Vitamin D deficiency in episodic migraine, chronic migraine and medication-overuse headache patients. <i>Journal of Headache and Pain</i> , 2015, 16, A184.	2.5	16
103	A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. <i>Epilepsia</i> , 2015, 56, 1162-1173.	2.6	44
104	Profile of brivaracetam and its potential in the treatment of epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2967.	1.0	14
105	The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. <i>Clinical Interventions in Aging</i> , 2015, 10, 1421.	1.3	76
106	Recurrence of atrial fibrillation after switching from brand to generic atenolol. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2015, 6, 39.	0.2	5
107	Effects of chronic sodium alendronate on depression and anxiety in a menopausal experimental model. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 129, 65-71.	1.3	25
108	Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract. <i>Chemico-Biological Interactions</i> , 2015, 229, 17-25.	1.7	21

#	ARTICLE	IF	CITATIONS
109	Bilateral lower limbs edema with "œwooden" character induced by insulin glargine treatment. <i>Acta Diabetologica</i> , 2015, 52, 809-811.	1.2	6
110	Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats. <i>Brain Research Bulletin</i> , 2015, 113, 1-7.	1.4	55
111	Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy. <i>British Journal of Pharmacology</i> , 2015, 172, 3177-3188.	2.7	46
112	Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats. <i>Neurotherapeutics</i> , 2015, 12, 250-262.	2.1	22
113	Are big potassium-type Ca ²⁺ -activated potassium channels a viable target for the treatment of epilepsy?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 911-926.	1.5	14
114	Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2355-2371.	0.9	33
115	Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice. <i>Molecular Metabolism</i> , 2015, 4, 528-536.	3.0	48
116	Long-term betamethasone 21-phosphate disodium treatment has distinct effects in CD1 and DBA/2 mice on animal behavior accompanied by opposite effects on neurogenesis. <i>Behavioural Brain Research</i> , 2015, 278, 155-166.	1.2	8
117	Hyperhomocysteinaemia and chronic venous ulcers. <i>International Wound Journal</i> , 2015, 12, 22-26.	1.3	32
118	Epilepsy associated with Leukoaraiosis mainly affects temporal lobe: a casual or causal relationship?. <i>Epilepsy Research</i> , 2015, 109, 1-8.	0.8	39
119	Drug-Drug Interactions: Antiretroviral Drugs and Recreational Drugs. <i>Recent Patents on CNS Drug Discovery</i> , 2015, 9, 153-163.	0.9	14
120	Gambling Disorder during Dopamine Replacement Treatment in Parkinson's Disease: A Comprehensive Review. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	19
121	Skin rash during treatment with generic itraconazole. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2014, 5, 158.	0.2	10
122	P2-086: CITICOLINE IN COGNITIVE IMPAIRMENT: AN OLD DRUG WITH NEW PERSPECTIVES. , 2014, 10, P502-P502.		1
123	Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy. <i>CNS Drugs</i> , 2014, 28, 939-949.	2.7	23
124	Effects of Phenobarbital and Levetiracetam on PR and QTc Intervals in Patients with Post-Stroke Seizure. <i>Clinical Drug Investigation</i> , 2014, 34, 879-886.	1.1	15
125	Use of atypical antipsychotics in the elderly: a clinical review. <i>Clinical Interventions in Aging</i> , 2014, 9, 1363.	1.3	87
126	Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 109-123.	0.7	86

#	ARTICLE	IF	CITATIONS
127	Targeting α -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 319-334.	1.5	40
128	Cerebral stroke injury: the role of cytokines and brain inflammation. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2014, 25, 131-137.	0.7	94
129	Targeting Mast Cells Tryptase in Tumor Microenvironment: A Potential Antiangiogenetic Strategy. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	52
130	Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1040-1048.	1.4	22
131	<i>Hypericum perforatum</i> : Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug Interactions. <i>Phytotherapy Research</i> , 2014, 28, 643-655.	2.8	138
132	Effects of Acetaminophen and Ibuprofen in Children With Migraine Receiving Preventive Treatment With Magnesium. <i>Headache</i> , 2014, 54, 313-324.	1.8	36
133	Rosacea-like facial rash related to metformin administration in a young woman. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 3.	1.0	12
134	Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. <i>Brain, Behavior, and Immunity</i> , 2014, 42, 157-168.	2.0	84
135	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. <i>Autoimmunity</i> , 2014, 47, 287-306.	1.2	16
136	Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. <i>Epilepsia</i> , 2014, 55, 1284-1291.	2.6	54
137	Adherence to therapy and adverse drug reactions: is there a link?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 41-55.	1.0	94
138	The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model. <i>Neurological Sciences</i> , 2014, 35, 1793-1799.	0.9	25
139	Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 637-644.	0.9	13
140	Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 322-329.	2.0	57
141	Lack of efficacy during the switch from brand to generic allopurinol. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2013, 20, 540-542.	0.5	9
142	A review on antiepileptic drugs-dependent fatigue: Pathophysiological mechanisms and incidence. <i>European Journal of Pharmacology</i> , 2013, 718, 10-16.	1.7	32
143	Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. <i>Updates in Surgery</i> , 2013, 65, 53-57.	0.9	38
144	Effects of Topiramate on Dysaesthetic Pain in a Patient with Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2013, 33, 151-154.	1.1	8

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Off-label Use of Fondaparinux in the Management of Heparin-induced Thrombocytopenia with Thrombosis in an Elderly Woman. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 999-1002.	1.0	4
146	Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR- α receptor activation in a genetic model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 115-126.	2.0	91
147	mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 25-36.	2.0	107
148	Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice. <i>Pharmacological Research</i> , 2013, 70, 1-12.	3.1	49
149	Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection. <i>Digestive and Liver Disease</i> , 2013, 45, 403-407.	0.4	58
150	CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. <i>Epilepsy Research</i> , 2013, 106, 74-82.	0.8	46
151	Lamotrigine positively affects the development of psychiatric comorbidity in epileptic animals, while psychiatric comorbidity aggravates seizures. <i>Epilepsy and Behavior</i> , 2013, 28, 232-240.	0.9	30
152	Phthalates: European regulation, chemistry, pharmacokinetic and related toxicity. <i>Environmental Toxicology and Pharmacology</i> , 2013, 36, 88-96.	2.0	237
153	Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. <i>Neuropharmacology</i> , 2013, 64, 371-379.	2.0	72
154	Vertigo/dizziness as a Drugs' adverse reaction. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S104-S109.	0.2	49
155	Pharmacovigilance in Italy: An overview. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S20-S28.	0.2	67
156	Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 78.	0.2	12
157	The safety of ketoprofen in different ages. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S99-S103.	0.2	13
158	Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S55-S60.	0.2	12
159	Pharmacovigilance in Calabria (Italy): Local experiences resonate international relevance. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 1.	0.2	2
160	Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. <i>Advances in Pharmacological Sciences</i> , 2013, 2013, 1-8.	3.7	30
161	Mast Cell Positivity to Tryptase Correlates with Metastatic Lymph Nodes in Gastrointestinal Cancer Patients Treated Surgically. <i>Oncology</i> , 2013, 85, 111-116.	0.9	57
162	Asterix as a Presentation of Cerebellar Ischemic Stroke. <i>Western Journal of Emergency Medicine</i> , 2013, 13, 507-508.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetic drug-drug interaction and their implication in clinical management. <i>Journal of Research in Medical Sciences</i> , 2013, 18, 601-10.	0.4	182
164	Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management. <i>Current Neuropharmacology</i> , 2012, 10, 254-262.	1.4	49
165	Synthesis and Biological Characterization of 3-Substituted 1 <i>H</i> -Indoles as Ligands of GluN2B-Containing <i>N</i> -Methyl-D-aspartate Receptors. Part 2. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10532-10539.	2.9	9
166	The impact of a vaccination campaign against hepatitis B on the further decrease of hepatitis B virus infection in a southern Italian town over 14years. <i>European Journal of Internal Medicine</i> , 2012, 23, e190-e192.	1.0	15
167	Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>Pharmacological Research</i> , 2012, 65, 285-296.	3.1	37
168	New AMPA antagonists in epilepsy. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1371-1389.	1.9	52
169	The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis. <i>Molecular Neurobiology</i> , 2012, 46, 662-681.	1.9	85
170	Primary breast cancer tryptase expression as novel molecular drug target.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21113-e21113.	0.8	0
171	Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. <i>Behavioural Brain Research</i> , 2011, 225, 373-376.	1.2	43
172	Synthesis and Biological Characterization of 3-Substituted-1 <i>H</i> -indoles as Ligands of GluN2B-Containing <i>N</i> -Methyl-D-aspartate Receptors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 8702-8706.	2.9	19
173	Fenbufen Pretreatment Potentiates the Anticonvulsant Activity of CPPene and NBQX in DBA/2 Mice. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 46, 1017-1022.	1.2	4
174	Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. <i>Epilepsia</i> , 2011, 52, 1341-1350.	2.6	71
175	Determinants of health-related quality of life in pharmaco-resistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. <i>Epilepsia</i> , 2011, 52, 2181-2191.	2.6	227
176	Preclinical activity profile of Î±-lactalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. <i>Epilepsy Research</i> , 2011, 95, 60-69.	0.8	41
177	Effects of Carbamazepine/Oxycodone Coadministration in the Treatment of Trigeminal Neuralgia. <i>Annals of Pharmacotherapy</i> , 2011, 45, e33-e33.	0.9	23
178	Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. <i>Epilepsia</i> , 2010, 51, 1560-1569.	2.6	75
179	Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 137-144.	0.8	43
180	Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. <i>Clinical Therapeutics</i> , 2010, 32, 2030-2034.	1.1	10

#	ARTICLE	IF	CITATIONS
181	Novel 3- <i>Carboxy</i> - and 3- <i>Phosphonopyrazoline</i> Amino Acids as Potent and Selective NMDA Receptor Antagonists: Design, Synthesis, and Pharmacological Characterization. <i>ChemMedChem</i> , 2010, 5, 1465-1475.	1.6	22
182	Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-resistant refractory epilepsy. <i>Epilepsia</i> , 2010, 51, 797-804.	2.6	160
183	Phenobarbital/Lamotrigine Coadministration-Induced Blood Dyscrasia in a Patient with Epilepsy. <i>Annals of Pharmacotherapy</i> , 2010, 44, 2031-2034.	0.9	21
184	A Case of Neuroleptic Malignant Syndrome Induced by Risperidone in a Schizophrenic Woman. <i>Current Drug Safety</i> , 2009, 4, 119-120.	0.3	7
185	Hepatotoxicity Induced by Methimazole in a Previously Health Patient. <i>Current Drug Safety</i> , 2009, 4, 204-206.	0.3	47
186	Sertraline-Induced Rhabdomyolysis in an Elderly Patient with Dementia and Comorbidities. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1354-1359.	0.9	21
187	The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. <i>BMC Biology</i> , 2009, 7, 24.	1.7	47
188	Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. <i>European Journal of Neuroscience</i> , 2009, 29, 1979-1993.	1.2	26
189	Altered distribution and function of A _{2A} adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. <i>European Journal of Neuroscience</i> , 2009, 30, 1023-1035.	1.2	43
190	T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. <i>Neuropharmacology</i> , 2009, 56, 637-646.	2.0	29
191	Idiopathic Hemifacial Spasm Responsive to Zonisamide. <i>Clinical Neuropharmacology</i> , 2009, 32, 230-231.	0.2	3
192	Neuroactive steroids and GABA _A receptor plasticity in the brain of the WAG/Rij rat, a model of absence epilepsy. <i>Journal of Neurochemistry</i> , 2008, 106, 2502-2514.	2.1	20
193	Effects of ethanol on the development of genetically determined epilepsies in rats. <i>International Journal of Developmental Neuroscience</i> , 2008, 26, 739-744.	0.7	14
194	Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy. <i>Epilepsy and Behavior</i> , 2008, 13, 295-299.	0.9	20
195	The safety of clozapine in the elderly. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 525-538.	1.0	53
196	Venlafaxine-Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation. <i>Annals of Pharmacotherapy</i> , 2008, 42, 434-438.	0.9	40
197	Role of CYP3A5 in Abnormal Clearance of Methadone. <i>Annals of Pharmacotherapy</i> , 2008, 42, 893-897.	0.9	26
198	Solution-Phase Parallel Synthesis of Novel 1,2,3,4-Tetrahydroisoquinolin-1-ones as Anticonvulsant Agents. <i>Chemical and Pharmaceutical Bulletin</i> , 2008, 56, 181-184.	0.6	12

#	ARTICLE	IF	CITATIONS
199	Psychic Disturbances Associated with Sodium Valproate Plus Levetiracetam. <i>Annals of Pharmacotherapy</i> , 2007, 41, 527-528.	0.9	10
200	Drugs Treatment of Pain in Multiple Sclerosis. <i>Current Clinical Pharmacology</i> , 2007, 2, 227-233.	0.2	10
201	Combined topiramate and declorazepam therapy in a patient affected by essential tremor. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 129-130.	1.1	7
202	Efficacy and Tolerability of Topiramate in Vascular Generalized Chorea. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1915-1915.	0.9	4
203	Apomorphine-induced neurodegeneration in Mongolian gerbil hippocampus. <i>Schizophrenia Research</i> , 2007, 95, 223-227.	1.1	2
204	Enantioseparation, absolute configuration determination, and anticonvulsant activity of (Å±)-1-(4-aminophenyl)-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-one. <i>Chirality</i> , 2007, 19, 16-21.	1.3	3
205	Synthesis of Conformationally Constrained Glutamic Acid Homologues and Investigation of Their Pharmacological Profiles. <i>ChemMedChem</i> , 2007, 2, 1639-1647.	1.6	14
206	Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>Epilepsy Research</i> , 2007, 75, 112-121.	0.8	37
207	Use of Topiramate for Glossodynia. <i>Pain Medicine</i> , 2007, 8, 531-534.	0.9	18
208	Adverse Effects of Atypical Antipsychotics in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 937-956.	1.3	73
209	Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 575-581.	2.9	35
210	Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Skeleton. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5618-5622.	2.9	32
211	Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. <i>Neuropharmacology</i> , 2006, 50, 1059-1071.	2.0	41
212	Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. <i>Neuropharmacology</i> , 2006, 51, 1058-1067.	2.0	33
213	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 167-170.	1.0	23
214	Amino acid levels in some brain areas of inducible nitric oxide synthase knock out mouse (iNOS ^{Δ/Δ}) before and after pentylenetetrazole kindling. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 804-812.	1.3	24
215	Synthesis of Novel 3-(Alkylcarbamoyl)-2-aryl-1,2-dihydro-6,7-(methylenedioxy)-3H-quinazolin-4-ones as Anticonvulsant Agents. <i>Chemistry and Biodiversity</i> , 2006, 3, 304-311.	1.0	4
216	3D Pharmacophore Models for 1,2,3,4-Tetrahydroisoquinoline Derivatives Acting as Anticonvulsant Agents. <i>Archiv Der Pharmazie</i> , 2006, 339, 388-400.	2.1	18

#	ARTICLE	IF	CITATIONS
217	Role of lifestyle factors on plasma homocysteine levels in Parkinson's disease patients treated with levodopa. <i>Nutritional Neuroscience</i> , 2006, 9, 11-16.	1.5	20
218	Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents. <i>Il Farmaco</i> , 2005, 60, 231-235.	0.9	6
219	Amino acid levels in some lethargic mouse brain areas before and after pentylenetetrazole kindling. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 47-53.	1.3	5
220	A questionnaire-based study on prevalence and treatment of headache in young children. <i>Journal of Headache and Pain</i> , 2005, 6, 277-280.	2.5	16
221	AMPA Receptor Antagonists as Potential Anticonvulsant Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 31-42.	1.0	70
222	Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	2.0	51
223	Melaena following Use of the Cholinesterase Inhibitor Rivastigmine. <i>Clinical Drug Investigation</i> , 2005, 25, 215-217.	1.1	16
224	Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. <i>Pharmacological Research</i> , 2005, 52, 367-375.	3.1	37
225	Generalized exfoliative dermatitis induced by interferon alfa. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2173-2174.	0.9	9
226	Acute encephalopathy induced by oxcarbazepine and furosemide. <i>Annals of Pharmacotherapy</i> , 2004, 38, 509-510.	0.9	9
227	Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 77, 85-94.	1.3	41
228	Seizure susceptibility to various convulsant stimuli of knockout interleukin-6 mice. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 77, 761-766.	1.3	62
229	Susceptibility to audiogenic seizure and neurotransmitter amino acid levels in different brain areas of IL-6-deficient mice. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 78, 75-81.	1.3	28
230	Influence of carbenoxolone on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2004, 484, 49-56.	1.7	34
231	Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives. <i>Il Farmaco</i> , 2004, 59, 7-12.	0.9	25
232	Synthesis and anticonvulsant activity of N-3 substituted 2,3-benzodiazepines. <i>Il Farmaco</i> , 2004, 59, 353-358.	0.9	7
233	Spinal myoclonus responsive to topiramate. <i>Movement Disorders</i> , 2004, 19, 1380-1381.	2.2	24
234	Design of 1-substituted 2-arylmethyl-4,5-methylenedioxybenzene derivatives as antiseizure agents. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 3703-3709.	1.4	10

#	ARTICLE	IF	CITATIONS
235	Levofloxacin-Induced Taste Perversion, Blurred Vision and Dyspnoea in a Young Woman. <i>Clinical Drug Investigation</i> , 2004, 24, 487-489.	1.1	14
236	Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. <i>Neuropharmacology</i> , 2004, 46, 865-878.	2.0	75
237	Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs). <i>Neuropharmacology</i> , 2004, 47, 1205-1216.	2.0	85
238	Seizure susceptibility to various convulsant stimuli in dystrophin-deficient mdx mice. <i>Neuroscience Research</i> , 2004, 50, 37-44.	1.0	34
239	Design, Synthesis, and Pharmacological Characterization of Novel, Potent NMDA Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6740-6748.	2.9	22
240	Discovery of a Novel and Highly Potent Noncompetitive AMPA Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 197-200.	2.9	80
241	Synthesis and Evaluation of Pharmacological Properties of Novel Annelated 2,3-Benzodiazepine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3758-3761.	2.9	48
242	Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists. <i>Journal of Chemical Information and Computer Sciences</i> , 2003, 43, 651-655.	2.8	39
243	1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4427-4430.	1.0	59
244	Glutamate metabotropic receptors as targets for drug therapy in epilepsy. <i>European Journal of Pharmacology</i> , 2003, 476, 3-16.	1.7	159
245	Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 74, 595-602.	1.3	57
246	Conventional and Atypical Antipsychotics in the Elderly. <i>Clinical Drug Investigation</i> , 2003, 23, 287-322.	1.1	40
247	Synthesis and Anticonvulsant Activity of Novel Bicyclic Acidic Amino Acids. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3102-3108.	2.9	26
248	Neuropharmacology of depression in aging and age-related diseases. <i>Ageing Research Reviews</i> , 2002, 1, 113-134.	5.0	62
249	Influence of some $\hat{1}^2$ -adrenoceptor antagonists on the anticonvulsant potency of antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2002, 442, 205-213.	1.7	27
250	Group III mGlu receptor agonists potentiate the anticonvulsant effect of AMPA and NMDA receptor block. <i>European Journal of Pharmacology</i> , 2002, 451, 55-61.	1.7	11
251	Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. <i>Il Farmaco</i> , 2002, 57, 129-134.	0.9	25
252	Novel Potent AMPA/Kainate Receptor Antagonists:Â Synthesis and Anticonvulsant Activity of a Series of 2-[(4-Alkylsemicarbazono)-(4-amino- phenyl)methyl]-4,5-methylenedioxyphenylacetic Acid Alkyl Esters. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4433-4442.	2.9	14

#	ARTICLE	IF	CITATIONS
253	Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 363, 330-336.	1.4	19
254	Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 463-466.	1.0	24
255	Influence of d-cycloserine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>Epilepsy Research</i> , 2000, 40, 109-121.	0.8	12
256	Benzodiazepine Receptor Affinities, Behavioral, and Anticonvulsant Activity of 2-Aryl-2,5-dihydropyridazino[4,3-b]indol-3(3H)-ones in Mice. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 65, 475-487.	1.3	12
257	Topiramate potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2000, 388, 163-170.	1.7	21
258	7-Nitroindazole potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2000, 394, 275-288.	1.7	36
259	NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2000, 408, 25-34.	1.7	47
260	Synthesis and Evaluation of Pharmacological and Pharmacokinetic Properties of 11H-[1,2,4]Triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4834-4839.	2.9	43
261	Synthesis and Anticonvulsant Activity of Novel and Potent 6,7-Methylenedioxyphthalazin-1(2H)-ones. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2851-2859.	2.9	193
262	Conventional and new antidepressant drugs in the elderly. <i>Progress in Neurobiology</i> , 2000, 61, 353-396.	2.8	111
263	Effects of compounds acting on GABAB receptors in the pentylenetetrazole kindling model of epilepsy in mice. <i>Neuropharmacology</i> , 2000, 39, 2147-2161.	2.0	40
264	Determination of new 2,3-benzodiazepines in rat plasma using high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 1999, 731, 207-215.	1.7	9
265	Synthesis and Anticonvulsant Activity of Novel and Potent 2,3-Benzodiazepine AMPA/Kainate Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4414-4421.	2.9	48
266	Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. <i>European Journal of Pharmacology</i> , 1999, 368, 149-159.	1.7	24
267	Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensitive DBA/2 mice. <i>European Journal of Pharmacology</i> , 1999, 371, 137-145.	1.7	67
268	Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists. <i>Il Farmaco</i> , 1999, 54, 178-187.	0.9	27
269	Anticonvulsant Activity and Plasma Level of 2,3-Benzodiazepin-4-ones (CFMs) in Genetically Epilepsy-Prone Rats. <i>Pharmacology Biochemistry and Behavior</i> , 1999, 63, 621-627.	1.3	18
270	Treatment of epilepsy in the elderly. <i>Progress in Neurobiology</i> , 1999, 58, 389-407.	2.8	35

#	ARTICLE	IF	CITATIONS
271	Enhanced susceptibility of pentylenetetrazole kindled mice to quinolone effects. <i>International Journal of Antimicrobial Agents</i> , 1999, 12, 239-244.	1.1	11
272	Synthesis and Enantiopharmacology of New AMPA-Kainate Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4099-4107.	2.9	42
273	IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion shock. <i>Journal of Leukocyte Biology</i> , 1999, 66, 471-480.	1.5	64
274	Relationship Between Anticonvulsant Activity and Plasma Level of Some 2,3-Benzodiazepines in Genetically Epilepsy-Prone Rats. <i>Pharmacology Biochemistry and Behavior</i> , 1998, 61, 215-220.	1.3	21
275	Antidepressant Drugs in the Elderly. <i>General Pharmacology</i> , 1998, 30, 465-475.	0.7	18
276	High-performance liquid chromatographic determination of new 2,3-benzodiazepines. <i>Biomedical Applications</i> , 1998, 705, 149-153.	1.7	15
277	Synthesis and Pharmacology of a New AMPA α -Kainate Receptor Agonist with Potent Convulsant Activity. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3759-3762.	2.9	11
278	Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. <i>European Journal of Pharmacology</i> , 1998, 349, 179-185.	1.7	38
279	3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: A New Class of AMPA Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3409-3416.	2.9	44
280	1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: A Novel AMPA Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1258-1269.	2.9	88
281	Comparative, behavioural and electrocortical effects of tumor necrosis factor- α and interleukin-1 microinjected into the locus coeruleus of rat. <i>Life Sciences</i> , 1997, 60, 555-564.	2.0	58
282	Effects of enalapril in rats with pressure overload cardiac hypertrophy. <i>General Pharmacology</i> , 1997, 28, 531-533.	0.7	1
283	Is the mitochondrial benzodiazepine receptor involved in the control of airway smooth muscle tone?. <i>General Pharmacology</i> , 1997, 28, 495-498.	0.7	5
284	Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997, 356, 48-55.	1.4	40
285	Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. <i>European Journal of Pharmacology</i> , 1996, 317, 239-245.	1.7	14
286	Impairment of immunological functions in genetically epilepsy-prone rats. <i>General Pharmacology</i> , 1996, 27, 643-646.	0.7	4
287	1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice. <i>General Pharmacology</i> , 1996, 27, 935-941.	0.7	17
288	Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy prone rats. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 55, 39-48.	1.3	17

#	ARTICLE	IF	CITATIONS
289	Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CFP 37849 and CGP 39551 in genetically epilepsy-prone rats. <i>Brain Research</i> , 1996, 734, 91-97.	1.1	11
290	Anticonvulsant activity of 5,7DCKA, NBQX, and felbamate against some chemoconvulsants in DBA/2 mice. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 55, 281-287.	1.3	8
291	Azirino [1, 2-d] [1, 4]benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice. <i>General Pharmacology</i> , 1996, 27, 1155-1162.	0.7	6
292	De novo epileptic confusional status in a patient with cobalamin deficiency. <i>Metabolic Brain Disease</i> , 1995, 10, 233-238.	1.4	9
293	Role of calcium in brain aging. <i>General Pharmacology</i> , 1995, 26, 1651-1657.	0.7	22
294	GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. <i>European Journal of Pharmacology</i> , 1995, 294, 411-422.	1.7	63
295	Anticonvulsant activity of pyrrolo[1,2- <i>b</i>]imidazo[4,5- <i>b</i>]pyridines, pyrrolo[2,3- <i>b</i>]imidazo[4,5- <i>c</i>]pyridines and pyrrolo[2,1- <i>f</i>]purines in DBA/2 mice. <i>General Pharmacology</i> , 1994, 25, 1027-1031.	0.7	8
296	Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. <i>European Journal of Pharmacology</i> , 1994, 262, 11-19.	1.7	62
297	Anticonvulsant effects of U-54494A and U-50488H in genetically epilepsy-prone rats and DBA/2 mice: A possible involvement of glycine/NMDA receptor complex. <i>General Pharmacology</i> , 1993, 24, 439-447.	0.7	19
298	Only some anticonvulsants protect against seizures induced by aminophylline in quinolone-treated genetically epilepsy prone rats. <i>General Pharmacology</i> , 1993, 24, 1393-1401.	0.7	2
299	Epileptogenic effects of skin extracts from the Australian frog <i>Pseudophryne coriacea</i> after intracerebral microinfusion in rats. <i>Toxicon</i> , 1992, 30, 197-201.	0.8	3
300	Excitatory neurotransmitters in the lateral habenula and pedunculopontine nucleus of rat modulate limbic seizures induced by pilocarpine. <i>Brain Research</i> , 1992, 591, 209-222.	1.1	28
301	Anticonvulsant activity of competitive antagonists of NMDA receptor in genetically epilepsy-prone rats. <i>European Journal of Pharmacology</i> , 1992, 215, 221-229.	1.7	33
302	Repeated treatment with quinolones potentiates the seizures induced by aminophylline in genetically epilepsy-prone rats. <i>General Pharmacology</i> , 1992, 23, 853-859.	0.7	11
303	Effects of antiepileptic drugs, calcium channel blockers and other compounds on seizures induced by activation of voltage-dependent L calcium channel in DBA/2 mice. <i>General Pharmacology</i> , 1992, 23, 1205-1216.	0.7	32
304	Anticonvulsant action of 2-chloroadenosine injected focally into the inferior colliculus and substantia nigra. <i>European Journal of Pharmacology</i> , 1991, 194, 145-152.	1.7	30
305	Effects of pertussis toxin, dibutyryl-cyclic-amp, bromo-cyclic-amp and forskolin on the behavioural and electrocortical power spectrum changes induced by microinfusion of interleukin-2 into the locus coeruleus. <i>International Journal of Neuroscience</i> , 1991, 59, 67-79.	0.8	5
306	Anticonvulsant properties of some calcium antagonists on sound-induced seizures in genetically epilepsy prone rats. <i>General Pharmacology</i> , 1990, 21, 769-778.	0.7	40

#	ARTICLE	IF	CITATIONS
307	Ventral tegmental area: site through which dopamine D ₂ -receptor agonists evoke behavioural and electrocortical sleep in rats. <i>British Journal of Pharmacology</i> , 1988, 95, 860-866.	2.7	56
308	Anticonvulsant action of a kainate antagonist ³ -D-glutamyl aminomethylsulphonic acid injected focally into the substantia nigra and entopeduncular nucleus. <i>European Journal of Pharmacology</i> , 1986, 132, 229-236.	1.7	40